N-Acetyl homotaurine
Content by: OpenSupplement Editorial Team | Medical review: pending | Last updated: April 13, 2026
TL;DR
Prescription acamprosate vs. OTC homotaurine — same base compound, different acetylation
Best tinnitus evidence: Azevedo 2005[1] study showed 87% improvement over 3 months
Works by reducing brain excitability and blocking amyloid-beta protein aggregation
Generally well-tolerated; avoid with severe kidney disease
Monthly cost: $20-40 for OTC homotaurine
Best for: tinnitus (experimental), alcohol recovery (prescription form), early cognitive decline research
What it is
N-acetyl homotaurine exists in two forms that showcase how a simple chemical modification can transform a supplement into a prescription drug. Acamprosate (the acetylated version) is FDA-approved for maintaining alcohol sobriety, while homotaurine (the base compound) is available over-the-counter and studied for tinnitus and brain protection.
The compound works through a fascinating dual mechanism: it blocks overactive NMDA receptors (which transmit excitatory "go" signals) while enhancing GABA-A receptors (which transmit calming "stop" signals). In the auditory system, this quiets the hyperactive nerve firing that creates phantom ringing sounds. In the brain, it may protect against the toxic protein clumps that characterize Alzheimer's disease.
This represents an interesting case study in supplement regulation — the same basic molecule with slightly different chemistry occupies completely different regulatory categories and price points.
What the research says
The Alzheimer's Connection Homotaurine (also called tramiprosate) directly inhibits the formation of amyloid-beta oligomers — the toxic protein clumps that damage brain cells in Alzheimer's disease. This isn't just test-tube activity; Phase III clinical trials showed it reduced hippocampal volume loss and slowed memory decline specifically in people carrying the APOE4 genetic risk variant.
Current Clinical Development While the original tramiprosate trials didn't meet primary endpoints, researchers developed ALZ-801 (valiltramiprosate), a prodrug version designed for better brain penetration. This compound is currently in Phase III trials, suggesting the mechanism remains promising despite initial setbacks.
Beyond Alzheimer's Preclinical studies show neuroprotective effects after traumatic brain injury, and the compound's ability to reduce brain excitotoxicity suggests broader applications for neurodegenerative conditions.
Practical Recommendation For cognitive decline prevention, this remains highly experimental. The OTC homotaurine available isn't the same formulation used in clinical trials, doses are much lower, and we lack long-term safety data for chronic use in healthy people. Consider it only if you're at high genetic risk and understand you're essentially participating in an uncontrolled experiment.
The Evidence Picture Homotaurine's tinnitus research centers on two small but intriguing studies. The Azevedo 2005 double-blind trial found that 87% of 50 participants experienced improvement over 3 months [1]. The more recent Farhadi 2020 study not only showed improved tinnitus scores but also measurable changes in inner ear electrical activity [2].
Why Results Are Mixed A 2021 meta-analysis pooling just 121 patients found no significant overall effect, highlighting how small sample sizes create statistical noise. However, a large network meta-analysis from Lancet eClinicalMedicine ranked homotaurine among effective pharmacologic treatments for tinnitus — suggesting the signal may be real but requires larger studies to detect consistently.
The Biological Rationale Tinnitus often involves hyperactive firing in auditory nerves — exactly what homotaurine's NMDA-blocking, GABA-enhancing mechanism should address. This isn't just theoretical; the Farhadi study actually measured improved cochlear function alongside symptom relief.
Practical Recommendation Given the limited evidence base, this remains experimental. However, the strong biological rationale, positive preliminary data, and excellent safety profile make it reasonable to try for 2-3 months in people with bothersome tinnitus who've exhausted standard approaches.
DISCLAIMER: The information on this page is for educational purposes only and has not been evaluated by the Food and Drug Administration. This content is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before using any dietary supplement, especially if you are pregnant, nursing, taking medication, or have a medical condition.
This page may contain affiliate links. If you purchase through these links, we may earn a small commission at no extra cost to you. Learn more.
N-Acetyl homotaurine on Amazon
Safety
Homotaurine has an excellent safety profile based on extensive clinical trial data from its prescription cousin acamprosate. The most common side effects are mild gastrointestinal issues — diarrhea, nausea, and stomach upset — affecting roughly 10-15% of users. These typically resolve within the first week of use.
The main contraindication is severe kidney disease, as the compound is eliminated primarily through the kidneys. Unlike many neuroactive compounds, homotaurine doesn't appear to cause dependence, withdrawal, or significant cognitive impairment. Long-term safety data comes primarily from acamprosate studies in alcohol-dependent populations, so we have less information about chronic use in healthy individuals taking OTC homotaurine.
Interactions
• Sedatives and sleep medications - may enhance drowsiness (minor to moderate) • Anti-epileptic drugs - potential additive effects on brain excitability (moderate) • Benzodiazepines - may potentiate GABA effects (moderate) • Alcohol - avoid combination, especially with prescription acamprosate (significant) • NMDA receptor antagonists (like memantine) - theoretical additive effects (unknown significance)
No significant interactions with cytochrome P450 enzymes, meaning it's unlikely to affect the metabolism of other medications.
Dosing
For Tinnitus OTC homotaurine: 333 mg twice daily with meals. The Azevedo study used this exact protocol [1]. Some practitioners recommend starting with once daily for the first week to assess tolerance.
For Cognitive Applications Experimental dosing: 100-200 mg daily. This is much lower than clinical trial doses but reflects what's practically available in OTC formulations.
Prescription Acamprosate If prescribed for alcohol dependence: 666 mg three times daily (total 2 grams). This requires normal kidney function and medical supervision.
Timing and Food Take with food to minimize stomach upset. Effects may take 4-8 weeks to become apparent for tinnitus, potentially longer for any cognitive effects. The compound has a relatively short half-life, so consistent daily dosing is important.
Cost
OTC homotaurine runs $20-40 monthly for typical doses, making it moderately expensive compared to basic vitamins but reasonable for a specialized neurological supplement. The compound isn't widely manufactured, limiting generic options and keeping prices elevated.
Prescription acamprosate is significantly more expensive without insurance ($200+ monthly) but may be covered for alcohol dependence treatment. The cost reflects limited manufacturing and the specialized nature of the compound rather than any inherent production complexity.
The bottom line
N-acetyl homotaurine occupies an interesting niche as a mechanistically rational but evidence-light supplement. The tinnitus data is intriguing but comes from small studies that need replication. For cognitive protection, you're essentially betting on a promising mechanism that hasn't yet translated to proven clinical benefit in the OTC formulation.
This makes sense for people with bothersome tinnitus who've tried standard approaches without success — the safety profile is excellent and the biological rationale is sound. For cognitive decline prevention, it's harder to recommend given the experimental nature and lower OTC doses. Anyone considering it should understand they're taking a calculated risk based on preliminary evidence rather than established benefit.
References
- Azevedo AA, Figueiredo RR. Tinnitus treatment with acamprosate: double-blind study. Braz J Otorhinolaryngol. 2005;71(5):618-623.
- Farhadi M, Mahmoudian S, Saddadi F, et al. Functional hearing changes in tinnitus patients under treatment with acamprosate. Iran J Otorhinolaryngol. 2020;32(108):31-40.
Sources for this page include published meta-analyses, systematic reviews, and NIH dietary supplement fact sheets. All claims reflect the evidence as of early 2026.
This is not medical advice. Consult your healthcare provider before starting any supplement, especially if you take medications.